SCHEMBL5895009

SCHEMBL5895009

Cc1ccccc1Oc1ccc(/C=C(/NC(=O)CCC2CCCC2)C(=O)O)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 4/20 0.49
PPARG P37231 1/20 0.49
LPAR1 Q92633 2/20 0.43
LPAR5 Q9H1C0 2/20 0.43
ALDH1A1 P00352 5/20 0.39
LMNA P02545 2/20 0.39
LDLR P01130 1/20 0.39
TDP1 Q9NUW8 2/20 0.39
LTA4H P09960 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
KLK7 P49862 1/20 0.38
HPGD P15428 2/20 0.38
NPC1 O15118 1/20 0.38
NFKB1 P19838 1/20 0.38
RAB9A P51151 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5894996 1.00 FFAR1 (0.49) FFAR1PPARGLPAR1LPAR5ALDH1A1
SCHEMBL5895016 1.00 FFAR1 (0.49) FFAR1PPARGLPAR1LPAR5ALDH1A1
SCHEMBL5895807 0.92 FFAR1 (0.44) FFAR1PPARGLPAR1LPAR5ALDH1A1
SCHEMBL5895814 0.92 FFAR1 (0.44) FFAR1PPARGLPAR1LPAR5ALDH1A1
SCHEMBL5895793 0.92 FFAR1 (0.44) FFAR1PPARGLPAR1LPAR5ALDH1A1
SCHEMBL5896564 0.90 NPSR1 (0.47) FFAR1LPAR1LPAR5ALDH1A1LMNA
SCHEMBL5894967 0.90 HSD17B10 (0.41) FFAR1PPARGALDH1A1TDP1MEN1
SCHEMBL5894990 0.90 HSD17B10 (0.41) FFAR1PPARGALDH1A1TDP1MEN1
SCHEMBL5896540 0.90 NPSR1 (0.47) FFAR1LPAR1LPAR5ALDH1A1LMNA
SCHEMBL5894980 0.90 HSD17B10 (0.41) FFAR1PPARGALDH1A1TDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7041690-B2 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY, LLC (US) 2006-05-09 US disclosed
US-20060004063-A1 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY, LLC 2006-01-05 US disclosed
EP-1532128-A1 INHIBITORS OF HCV NS5B POLYMERASE Pharmacia & Upjohn Company LLC (US) 2005-05-25 EP disclosed
WO-2004002977-A1 INHIBITORS OF HCV NS5B POLYMERASE PHARMACIA & UPJOHN COMPANY LLC (US) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004063-A1 Inhibitors of HCV NS5B polymerase POLRMT, EIF5B, POLI FFAR1 3738/4885PPARG 2568/4885LPAR1 3168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.